vs
Side-by-side financial comparison of Applied Therapeutics, Inc. (APLT) and Phunware, Inc. (PHUN). Click either name above to swap in a different company.
Phunware, Inc. is the larger business by last-quarter revenue ($1.0M vs $1.0M, roughly 1.0× Applied Therapeutics, Inc.). Phunware, Inc. runs the higher net margin — -260.2% vs -1899.0%, a 1638.8% gap on every dollar of revenue. On growth, Applied Therapeutics, Inc. posted the faster year-over-year revenue change (719.7% vs -21.9%).
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.
Phunware Inc. is a publicly traded enterprise software company headquartered in Austin, Texas. Founded in 2009, Phunware builds cloud-based platforms that help brands and governments engage users across mobile and digital environments. Its core products include solutions for mobile app development, location-based services, digital advertising, and data-driven engagement.
APLT vs PHUN — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.0M |
| Net Profit | $-19.0M | $-2.6M |
| Gross Margin | — | 46.5% |
| Operating Margin | -1675.8% | -290.2% |
| Net Margin | -1899.0% | -260.2% |
| Revenue YoY | 719.7% | -21.9% |
| Net Profit YoY | 72.3% | 59.7% |
| EPS (diluted) | $-0.13 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $1.0M | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | $0 | — | ||
| Q4 24 | $-1.0K | — | ||
| Q2 24 | $144.0K | $1.0M | ||
| Q1 24 | $190.0K | $921.0K | ||
| Q4 23 | $-667.0K | $941.0K | ||
| Q3 23 | $0 | $1.3M |
| Q3 25 | $-19.0M | — | ||
| Q2 25 | $-21.3M | — | ||
| Q1 25 | $-21.8M | — | ||
| Q4 24 | $44.0M | — | ||
| Q2 24 | $2.9M | $-2.6M | ||
| Q1 24 | $-83.9M | $-2.3M | ||
| Q4 23 | $-37.7M | $-23.0M | ||
| Q3 23 | $-42.4M | $-19.0M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | 46.5% | ||
| Q1 24 | — | 56.9% | ||
| Q4 23 | — | 47.5% | ||
| Q3 23 | — | 50.4% |
| Q3 25 | -1675.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3302300.0% | — | ||
| Q2 24 | -14194.4% | -290.2% | ||
| Q1 24 | -11101.6% | -312.1% | ||
| Q4 23 | 3149.3% | -2086.3% | ||
| Q3 23 | — | -1060.5% |
| Q3 25 | -1899.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -4400700.0% | — | ||
| Q2 24 | 2012.5% | -260.2% | ||
| Q1 24 | -44177.9% | -248.9% | ||
| Q4 23 | 5649.0% | -2445.6% | ||
| Q3 23 | — | -1515.9% |
| Q3 25 | $-0.13 | — | ||
| Q2 25 | $-0.15 | — | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | $0.52 | — | ||
| Q2 24 | $-0.13 | $-0.32 | ||
| Q1 24 | $-0.67 | $-0.33 | ||
| Q4 23 | $-0.40 | — | ||
| Q3 23 | $-0.47 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.9M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-561.0K | $14.1M |
| Total Assets | $34.4M | $23.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $11.9M | — | ||
| Q2 25 | $30.4M | — | ||
| Q1 25 | $50.8M | — | ||
| Q4 24 | $79.4M | — | ||
| Q2 24 | $122.2M | $20.4M | ||
| Q1 24 | $146.5M | $21.6M | ||
| Q4 23 | $49.9M | $3.9M | ||
| Q3 23 | $37.5M | $2.9M |
| Q3 25 | $-561.0K | — | ||
| Q2 25 | $17.4M | — | ||
| Q1 25 | $36.7M | — | ||
| Q4 24 | $57.0M | — | ||
| Q2 24 | $72.4M | $14.1M | ||
| Q1 24 | $67.3M | $14.6M | ||
| Q4 23 | $-17.1M | $-11.5M | ||
| Q3 23 | $-11.0M | $6.6M |
| Q3 25 | $34.4M | — | ||
| Q2 25 | $37.3M | — | ||
| Q1 25 | $56.9M | — | ||
| Q4 24 | $86.7M | — | ||
| Q2 24 | $127.8M | $23.1M | ||
| Q1 24 | $151.2M | $24.3M | ||
| Q4 23 | $54.8M | $6.7M | ||
| Q3 23 | $45.2M | $27.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.4M | $-2.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-18.4M | — | ||
| Q2 25 | $-20.3M | — | ||
| Q1 25 | $-28.6M | — | ||
| Q4 24 | $-19.5M | — | ||
| Q2 24 | $-22.6M | $-2.7M | ||
| Q1 24 | $-18.9M | $-5.5M | ||
| Q4 23 | $-17.0M | $-2.6M | ||
| Q3 23 | $-14.7M | $-3.3M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 0.0% | ||
| Q3 23 | — | 0.0% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.44× | — | ||
| Q2 24 | -7.80× | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
